HSE confirms €2.3m investment to improve cancer services in the south west
HSE South West has announced the "major" investment by the National Cancer Control Programme (NCCP) to improve cancer care across the region over the next 18 months.
The funding will support eight new projects and create 16.5 new healthcare jobs, including nurses, doctors and oncology support staff.
The new posts include specialist nursing support for patients in the rapid access lung service, a new family breast cancer pathway, which will aid in early detection, and a new post for a regional team supporting adolescents and young adults with cancer.
It will also include recruitment of a new patient support worker for breast cancer patients as well as recruitment of a senior occupational therapist and speech and language therapist to support an increased number of patients and families.
HSE South West regional executive officer, Dr Andy Phillips, said the investment shows a deep commitment to improve cancer care for everyone in the region.
He said:
It's not just about funding - it's about compassion, care and trust.
"We are building services that people can rely on during some of the most difficult times in their lives. With this support, we can offer faster diagnosis, better treatment, and more help for families and survivors.
"Our teams are dedicated to delivering care with kindness and professionalism, and this funding will help us do even more for our communities," Dr Phillips said.
The HSE said the investment "will bring tangible improvements to cancer services, with additional staff for early cancer diagnosis clinics and extra supports for families at risk of cancer".
Additional new services will also be developed, such as the provision of special care for teenagers and young adults with cancer, and the development of personalised cancer treatment expertise.
The new services will support people after their treatment ends and some of the funding will go toward the acute oncology service, helping cancer patients avoid the emergency departments.
CUH clinical director of cancer services Dr Dearbhaile Collins said: 'These additional staff will support many essential services across the region. Importantly, they will provide specialised care to our adolescent and young adult patients with cancer, patients on oral anti-cancer treatments, and the ongoing care of our cancer survivors.
"Furthermore, they will reinforce our family history clinics to improve early detection, rapid access clinics, bladder cancer surgical care and the crucial acute oncology services.
"We are also proud to announce that one of these positions will enable the region to lead out on the national molecular tumour board programme.'
Most of these new staff will be based at Cork University Hospital, with some roles located at Mercy University Hospital and University Hospital Kerry. Recruitment for the new oncology staff members is progressing.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Irish Sun
an hour ago
- The Irish Sun
Defib locations should be on Google Maps – it's matter of life and death, says Irish Senator in ‘critical access' plea
THE location of defibrillators on Google Maps would mean the difference between "life and death", a Fine Gael Senator has said. 2 Senator Boyle called for collaboration between the HSE and Google Credit: PR Handout 2 Defibrillators are essential life saving tools in cases of heart attack or cardiac arrest Credit: Getty Images - Getty The life-saving tools, automated external defibrillators, increase chances of survival in cases of heart attack or cardiac arrest. They allow for treatment before paramedics can arrive at the scene. Senator Boyle believes more can be done to make these essential tools more visible, after struggling to find one himself during an incident. He said: 'In an emergency when time is of the essence, knowing where the nearest AED is located in a community literally means the difference between life and death. READ MORE ON IRISH NEWS "Unfortunately, I had the experience of intervening in an incident when a person required a defibrillator. When another bystander and I checked two locations where we thought we might find the device, none could be found." The The However, Senator Boyle added: 'According to the NAS, many AEDs are never used because emergency services don't know where they are or how to access them. MOST READ IN THE IRISH SUN 'A search on Google Maps can show up some publicly accessible AEDs. However, I would call on the HSE to work with Google by providing it with its list of registered defibrillators so the coordinates of as many devices as possible can be found on Google Maps." There are currently a number of apps available showing the location of defibrillators. 'SAVE CRUCIAL TIME' However, Senator Boyle believes "having the AEDs displayed on Google Maps would save crucial time as directions are then easily accessible on a smartphone." He adds: 'The NAS currently works with community first responders, voluntary services, and members of the public to locate as many AEDs as possible nationally. "Technology providers can also play a role to ensure they have accurate information on a mapping and navigation service that can be used by the public in emergency situation, as that knowledge can save lives."
Irish Independent
7 hours ago
- Irish Independent
'We said thank you to Joe from the ladies of Ireland' – Louth breastcare provider on Joe Duffy's last show
Louth businesswoman Alison McCabe, who runs the Breastcare by Alison service for women who have had mastectomies while undergoing treatment for breast cancer, was among the guests at Joe Duffy's final Liveline Show on Friday June 2 Alison along with Caroline Davis from Caroline's Breastcare in Carlow were invited to the RTE studios for Joe's last show as they had featured on Liveline in May 2024 when Joe gave them a platform to speak against HSE proposals to cut funding allowances for women who had breast cancer.
RTÉ News
12 hours ago
- RTÉ News
Payments from drug firms to health professionals widespread, review finds
A new review has found that the practice of drug company payments to healthcare professionals and health organisations in Ireland is widespread. It recommends that the Health Service Executive should highlight that it does not support pharmaceutical industry payments to HSE healthcare professionals, accepting that such payments may influence behaviour in a negative way in terms of prescribing medicines. Data analysis for 2023 for the study shows that drug companies in Ireland made 4,509 payments to healthcare professionals and healthcare organisations, amounting to over €14.4m that year. The highest individual payment during the year by a drug company was €50,462 to a medical practitioner. There were 3,508 payments to healthcare professionals, amounting to €5.5m and 64 payments that exceeded €8,000. The review was conducted by Professor Michael Barry, Clinical Director of the National Centre for Pharmacoeconomics, which conducts assessments on the cost effectiveness of medicines for the HSE to consider, when making decisions on whether medicines should be made available for the public system. Prof Barry has advised the HSE that it should demand a 100% disclosure rate for all healthcare professionals and healthcare organisations in receipt of payments from the pharmaceutical industry. In his review of the 2023 payments, Prof Barry says that drug companies fund many healthcare settings, like hospitals and universities, where education and professional development take place. The industry also funds some medical societies. Prof Barry said the concern is not only are some societies involved in the education, research and development of prescribers, but some may also be involved in generating treatment guidelines. The payments by companies are publicly disclosed in accordance with the Irish Pharmaceutical Healthcare Association (IPHA) code of practice since 2016. The details on the public website come from up to 50 companies, including non-IPHA members. The payments, officially called Transfer of Value, are made for research and development, donations and sponsorship (including medical education), consultancy fees, registration fees for health staff and travel costs to attend events. The company that made the greatest number of payments to healthcare professionals was Novartis, with 374 such payments. Abbvie paid the most to healthcare professionals, amounting to €880,952. Prof Barry said that many would consider that the pharmaceutical industry should not have any role in the education of healthcare professionals and prescribers. He said that the medical literature has highlighted that doctors with ties to industry may be more inclined than their colleagues to prescribe a brand name drug, despite the availability of a cheaper generic version. Pharmaceutical industry 'committed to integrity and transparency' The Irish Pharmaceutical Healthcare Association (IPHA) said that under the latest data for 2024, a record level of 98% of healthcare professionals had provided named transparency on the payments received. It said that since 2016, companies have disclosed the financial payments, whether direct, or indirect, in cash or in kind, made to healthcare professionals and healthcare organisations. It also said that the latest data for 2024, just published, shows that payments to healthcare professionals came to €5.6m, a 4% decrease on the 2023 figure. It added that €178,169 was paid to 74 unnamed healthcare professionals last year, according to the data. The IPHA said the total amount paid to healthcare organisations last year was also down 3%, at over €8.6m, compared to the previous year. All healthcare organisations in receipt of the payments were disclosed individually last year, which the association said meant 100% transparency. The IPHA said that while its members are required to disclose the payments, currently, of the 51 companies who publish their data through the platform, 11 are non-IPHA members and 40 are IPHA members. The association said it is committed to integrity and transparency in all these interactions and the aim is to reach 100% named disclosure for healthcare professionals and it will support member companies in using legitimate interest, as a legal basis for making these disclosures under data protection law.
